Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06945120 · ClinicalTrials.gov registry record · NA
ACT Lung Health Intervention: Phase Two
A NA study of Smoking Cessation and Smoking Behaviors, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 2
- Study locations
NCT06945120: Recruiting NA study of Smoking Cessation and Smoking Behaviors, sponsored by Dana-Farber Cancer Institute.
NCT06945120 is a NA study of Smoking Cessation and Smoking Behaviors that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 50 participants, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06945120, a NA study of Smoking Cessation and Smoking Behaviors, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study aims to test a counseling and educational program designed to improve lung health through smoking cessation for Chinese and Korean American smokers at high risk for lung cancer.
Primary Outcome
The proportion of participants who have not smoked cigarettes (not even a puff) in the past 7 days at the 6-month follow-up, verified biochemically using salivary cotinine testing. Participants reporting abstinence and not using nicotine replacement therapy (NRT) will perform a salivary cotinine test observed via video call. Cotinine levels ≤3 ng/mL will confirm abstinence.
Conditions Studied
Interventions
- BEHAVIORAL ACT Lung Health Intervention
Study Locations (2)
Massachusetts
- Dana-Farber Cancer Institute - Boston
- University of Massachusetts-Boston - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-11-04 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What NCT06945120 shows while recruiting
NCT06945120 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (89% lower).
The record links to 5 conditions, with Smoking Cessation appearing as the primary indexed condition, and to 1 intervention - of which ACT Lung Health Intervention is the first listed.
NCT06945120 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06945120 about?
NCT06945120 is a clinical study titled "ACT Lung Health Intervention: Phase Two". This study aims to test a counseling and educational program designed to improve lung health through smoking cessation for Chinese and Korean American smokers at high risk for lung cancer.
What is the current status of trial NCT06945120?
This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2025-11-04. Estimated completion is 2026-12-31.
What conditions does trial NCT06945120 study?
This clinical trial studies the following conditions: Smoking Cessation, Smoking Behaviors, Smoking, Cigarette, Smoking, Tobacco, Smoking (Tobacco) Addiction.
What interventions are being tested in trial NCT06945120?
The interventions under investigation include: ACT Lung Health Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT06945120?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06945120 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06945120's enrollment target sits among peer trials
50 145th of 188 higher than 38 of 188 other Smoking Cessation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clinical Research Evaluating Smoking Cessation With E-Cigarettes and Nicotine Therapy
RECRUITING · NA
-
Scalable TELeheaLth Cancer CARe: The STELLAR Program to Treat Cancer Risk Behaviors
RECRUITING · NA
-
Refer2Quit: Evaluating a Proactive, Tailored, Population Health Approach for Tobacco Treatment for Household Smokers Through a Pediatric Care Network
RECRUITING · NA
-
Baby Steps III: Testing a Clinician and Patient Intervention to Promote Smoking Cessation Among Pregnant Women
RECRUITING · NA
-
Urban and Reservation Implementation of All Nations Breath of Life
RECRUITING · NA
-
Remote Smoking Cessation in Hospitalized Cardiac Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI